Navigation Links
Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55
Date:10/26/2011

ily of amortization related to purchased intangible assets associated with acquisitions. Excluding such items, gross margins would have been approximately 48%. Prior year gross profit is also impacted by similar purchase accounting related items in the amount of $74.6 million. Excluding such items, gross margins in the prior year would have been approximately 48%.

Earnings from operations were $265.9 million for the three months ended September 30, 2011, compared to $234.3 million for the comparable prior year period.  Excluding the impact of purchase accounting related items in both periods, as mentioned above, earnings from operations increased to $370.0 million in the current quarter from $308.9 million in the comparable prior year period. This increase was driven by higher gross profit in the current year as a result of the increase in revenues, partially offset by increases in selling, general and administrative costs (SG&A).Interest expense for the three months ended September 30, 2011, totaled $85.8 million, compared to $87.5 million for the comparable prior year period. Included in interest expense for the current quarter and the comparable prior year period are $12.6 million and $17.6 million of expense primarily related to the amortization of the discounts on our convertible debt instruments and 2018 Senior Notes, net of amortization of the premium on our 2020 Senior Notes.

Other income (expense), net, was income of $12.1 million in the current quarter compared to expense of $15.3 million in the comparable prior year period. Generally included in other income (expense), net, are interest and dividend income and foreign exchange gains and losses.

EBITDA, which is defined as net income (loss) (excluding the non-controlling interest and income from equity method investees) plus income taxes, interest expense, depreciation and amortization, was $419.7 million for the quarter ended September 30, 2011, and $327.1 million for t
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
2. Life Technologies Announces Third Quarter 2011 Results
3. Insmed to Host 2011 Third Quarter Earnings Conference Call
4. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
5. Anthera Announces Third Quarter 2011 Financial Report and Conference Call
6. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
7. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
8. HeartWare Schedules Third Quarter Conference Call and Webcast
9. Dyadic International Announces Date and Time of Third Quarter 2011 Financial Results Release and Conference Call
10. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
11. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , Collaboration with the ... in treatment of mastitis , ... to begin in the second half 2013 ... Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) will collaborate ... Service (ARS) to develop and trial products targeting the ...
(Date:5/20/2013)... 20, 2013 Oven Industries Inc. announces ... capabilities. The 5R6-900 benchtop controller has many outstanding user-friendly ... be plugged into the wall as a self-contained temperature ... distinctive detail makes the device unique, as well as ... temperature controller can also be used universally, which allows ...
(Date:5/20/2013)... 2013 Today, at the American Psychiatric Association ... James McGough , M.D., M.S., principal ... Institute for Neuroscience and Human Behavior and ... University of California Los Angeles (UCLA), and director of ... and ADHD at UCLA, presented the results of a ...
(Date:5/20/2013)... SAN DIEGO , May 20, 2013  Dr. ... the field of nucleic acid research, recently launched a ... Zone In with Zon ( zon.trilinkbiotech.com ), focuses on ... posts include interviews with industry thought leaders, discussions of ... publications and more. Dr. Zon (PhD ...
Breaking Biology Technology:Phosphagenics Signs Research Agreement with the Agricultural Research Service 2New Laboratory Temperature Controller by Oven Industries 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2
... Investment Conference on... -- HARBIN, China, Sept. 7 /PRNewswire-Asia-FirstCall/ -- ... ... --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... Calif., Sept. 7 / PRNewswire/ -- Transdel ... announced that Transdel management will present a company overview at ... York City on Monday, September 13, 2010 at 4:05 p.m. ... webcast via the Internet by visiting the Investor Relations section ...
... Exclusive Partnership Agreements for Immunotherapy Tablets in Japan -- ANTONY, France, September 6, 2010 ... ... --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Biology Technology:Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 2Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 3Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 4Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 5Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 6Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 7Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference 2Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference 3Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 2Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 3Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 4Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 5Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 6Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 7Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 8Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 9
(Date:5/20/2013)... of the planet, inhales carbon dioxide as it exudes oxygen. ... that eventually fall to the ground to decompose or get ... recently people believed much of the rain forest,s carbon floated ... ocean. University of Washington research showed a decade ago that ... open the question of how that was possible, since bark ...
(Date:5/20/2013)... University of Bristol and published online today in the ... how the brain and inner ear developed in dinosaurs. ... Sciences, together with Tom Hbner from the Niederschsische Landesmuseum ... year old dinosaurs. , The two palaeontologists studied different ... a very young (juvenile) individual of approximately three ...
(Date:5/19/2013)... of California, Davis have engineered a strain of photosynthetic ... They report their findings today at the 113th General ... this work, we used synthetic biology approaches to probe ... light energy for growth) cyanobacterial metabolism for the ability ... lead researcher on the study. He is part ...
Breaking Biology News(10 mins):Amazon River exhales virtually all carbon taken up by rain forest 2Amazon River exhales virtually all carbon taken up by rain forest 3Fossil brain teaser 2
... newborn described as a "happy blue baby" because of ... small mark in medical history when one of her ... River mutation. Scientists have identified hundreds of mutations ... protein that carries oxygen in everyone,s red blood cells. ...
... Bethesda, MD "Super bugs," which can cause wide-spread disease ... conventional antibiotics, still have their weaknesses. A team of ... presented in lipid (fatty) mixtures can significantly boost the ... This discovery was published online in The FASEB ...
... has awarded the University of Colorado Boulder a ... of long-term ecological changes in Colorado,s high mountains, ... Awarded to CU-Boulder,s Institute of Arctic and ... and students, including undergraduates, to continue key environmental ...
Cached Biology News:Hematologist discovers, names the 'Toms River' blood mutation in N.J. family 2Scientists develop a fatty 'kryptonite' to defeat multidrug-resistant 'Super bugs' 2NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research 2NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research 3NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research 4
OptiBuffer is a fully optimised medium, designed for,the electroporation of eukaryotic cells. OptiBuffer,improves both transfection efficiencies and survival,rates over PBS or other standard culture...
...
... interferons are cytopathic effect inhibition assays, also known ... include; tissue culture supernatents; serum from PK studies ... unit is defined as the quantity of interferon ... of viral infection by 50%. All ...
... interferons are cytopathic effect inhibition assays, also known ... include; tissue culture supernatents; serum from PK studies ... unit is defined as the quantity of interferon ... of viral infection by 50%. All ...
Biology Products: